Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylamidine SCHEMBL31307218 | 0.92 | MTNR1A (0.58) | MTNR1AMTNR1BMAOBLMNAALDH1A1 | |
| Xylamidine SCHEMBL123846 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BMAOBALDH1A1 | |
| SCHEMBL30201287 | 0.75 | MTNR1A (0.56) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL31231248 | 0.73 | MTNR1A (0.48) | MTNR1AMTNR1BLMNAALDH1A1 | |
| SCHEMBL30200767 | 0.71 | MTNR1A (0.42) | MTNR1AMTNR1BLMNAALDH1A1 | |
| 1,3-Dimethoxybenzene SCHEMBL11452224 | 0.70 | LMNA (0.58) | MTNR1AMTNR1BLMNA | |
| SCHEMBL30201095 | 0.70 | MTNR1A (0.52) | MTNR1AMTNR1BLMNAALDH1A1 | |
| SCHEMBL31231364 | 0.70 | MTNR1A (0.56) | MTNR1AMTNR1BLMNAALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5658158 | 0.69 | CTBP2 (0.55) | CTBP2 | |
| Xylamidine SCHEMBL2107805 | 0.68 | MAOB (0.47) | MTNR1AMTNR1BMAOBCTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | MTNR1A 84/4885MTNR1B 57/4885MAOB 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.